Literature DB >> 33948345

LncRNAs link cancer stemness to therapy resistance.

Jing Yue1, Yueguang Wu2, Liqing Qiu1, Ruping Zhao3, Mingfeng Jiang4, Hongfang Zhang1,5.   

Abstract

Cancer stem cells (CSCs) are a cellular subpopulation accelerating cancer cell growth, invasion and metastasis and survival. After chemoradiotherapy, CSCs are enriched because of their survival advantages and lead to tumor relapse and metastasis. Elimination of CSCs is critically important for the radical treatment of human cancers. Long non-coding RNAs (lncRNAs) are a group of RNAs longer than 200 nucleotides and have no protein-coding potential. Aberrant expressions of lncRNAs are associated with human diseases including cancer. LncRNAs function as cancer biomarkers, prognostic factors and therapeutic targets. They induce cancer stemness by chromatin modification, transcriptional regulation or post-transcriptional regulation of target genes as a sponge or through assembling a scaffold complex. Several factors caused aberrant expressions of lncRNAs in CSCs such as genes mutations, epigenetic alteration and environmental stimuli. Targeting of lncRNAs has been demonstrated to significantly reverse the chemoradioresistance of CSCs. In this review, we have summarized the progress of studies regarding lncRNAs-mediated therapy resistance of CSCs and clarified the molecular mechanisms. Furthermore, we have for the first time analyzed the influences of lncRNAs on cell metabolism and emphasized the effect of tumor microenvironment on lncRNAs functions in CSCs. Overall, the thorough understanding of the association of lncRNAs and CSCs would contribute to the reversal of therapy resistance. AJCR
Copyright © 2021.

Entities:  

Keywords:  Cancer stem cells; anti-cancer targets; long non-coding RNAs; molecular mechanisms; therapy resistance

Year:  2021        PMID: 33948345      PMCID: PMC8085841     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  4 in total

Review 1.  The potential roles and mechanisms of non-coding RNAs in cancer anoikis resistance.

Authors:  Tongguo Shi; Chuanqiang Zhang; Suhua Xia
Journal:  Mol Cell Biochem       Date:  2022-02-10       Impact factor: 3.396

2.  CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway.

Authors:  Zhengle Zhang; Longjiang Chen; Chuanbing Zhao; Qiong Gong; Zhigang Tang; Hanjun Li; Jing Tao
Journal:  Cell Biol Toxicol       Date:  2022-08-01       Impact factor: 6.819

Review 3.  Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma.

Authors:  José A Peña-Flores; Mercedes Bermúdez; Rosalío Ramos-Payán; Carlos E Villegas-Mercado; Uriel Soto-Barreras; Daniela Muela-Campos; Alexis Álvarez-Ramírez; Brenda Pérez-Aguirre; Ana D Larrinua-Pacheco; César López-Camarillo; Jorge A López-Gutiérrez; Julio Garnica-Palazuelos; Marvin E Estrada-Macías; Juan L Cota-Quintero; Andrés A Barraza-Gómez
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 4.  Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy.

Authors:  Giasemi C Eptaminitaki; Nora Wolff; Dimitris Stellas; Konstantinos Sifakis; Stavroula Baritaki
Journal:  Cells       Date:  2021-11-26       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.